TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Stopped Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.

Conditions

• Hepatitis C Virus

Interventions

• DRUG: placebo.
• DRUG: placebo.
• DRUG: TMC649128.
• DRUG: placebo.
• DRUG: placebo
• DRUG: TMC649128
• DRUG: TMC649128.
• DRUG: TMC649128
• DRUG: TMC649128.
• DRUG: placebo.

Sponsor

Tibotec BVBA